|
|
|
Article Cited by others LCC-A SYMPOSIUM-EDITORIAL
Personalized medicine: Lung Cancer leads the way
Parikh P, Puri T
Year : 2013| Volume: 50| Issue : 2 | Page no: 77-79 | This article has been cited by | | 1 |
Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India |
|
| | Purvish M. Parikh, Gouri Shankar Bhattacharyya, Ghanshyam Biswas, Arvind Krishnamurty, Dinesh Doval, Anil Heroor, Sanjay Sharma, Ramakant Deshpande, Harit Chaturvedi, S. P. Somashekhar, Govind Babu, G. Krishna Reddy, Diptendra Sarkar, Chirag Desai, Hemant Malhotra, Nitesh Rohagi, Ajay Bapna, S. S. Alurkar, Prasad Krishna, S. V.S. Deo, Anurag Shrivastava, Prakash Chitalkar, Saroj Kumar Majumdar, Devanhalli Vijay, Aniket Thoke, K. S. Udupa, Jyoti Bajpai, G. K. Rath, Palanki Satya Dattatreya, Shailesh Bondarde, Shekhar Patil | | | South Asian Journal of Cancer. 2021; 10(04): 213 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Advanced lung cancer and molecular testing in the middle of coronavirus disease 2019 second wave in the South Asian association for regional cooperation region |
|
| | Purvish Parikh, Akhil Kapoor, Kshitij Joshi, Indu Bansal, Vamshi Krishna, Tarini P. Sahoo, Randeep Singh, Ghanshyam Biswas, Raja Thirumalairaj, Rajendra Baral, A. F. M. Kamaluddin, Zeba Aziz, Amit Bhatt, K. Govind Babu | | | International Journal of Molecular & Immuno Oncology. 2021; 6: 61 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Why we should rely only on molecular tests based on Indian data |
|
| | Purvish M. Parikh, Randeep Singh | | | International Journal of Molecular & Immuno Oncology. 2020; 5: 44 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Editorial - T790M mutation and clinical outcomes with genuine osimertinib |
|
| | Purvish M Parikh | | | Indian Journal of Medical and Paediatric Oncology. 2019; 40(01): 7 | | | [Pubmed] [Google Scholar] [DOI] | | | 5 |
Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association betweenEGFRmutation status and survival outcome |
|
| | F. Li,X. Du,H. Zhang,T. Ju,C. Chen,Q. Qu,X. Zhang,L. Qi,G. Lizée | | | Clinical Genetics. 2017; 91(3): 488 | | | [Pubmed] [Google Scholar] [DOI] | | | 6 |
Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC |
|
| | Rafael Rosell,Elia Neninger,Marianne Nicolson,Rudolf M. Huber,Sumitra Thongprasert,Purvish M. Parikh,Erik D’Hondt | | | Journal of Thoracic Oncology. 2016; 11(11): 1954 | | | [Pubmed] [Google Scholar] [DOI] | |
|
|
